Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1994-12-15
1998-12-22
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
435 693, 424 931, A61K 39245, A61K 39255, A01N 6300, C12P 2106
Patent
active
058515330
ABSTRACT:
Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of glycoproteins of the organism, that have been prepared via recombinant means, and preferably C-truncated versions thereof. These glycoproteins when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.
REFERENCES:
patent: 4317811 (1982-03-01), Bertland et al.
patent: 4374127 (1983-02-01), Larson et al.
patent: 4442205 (1984-04-01), Hamer et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4618578 (1986-10-01), Burke et al.
patent: 4818694 (1989-04-01), Watson et al.
patent: 4855224 (1989-08-01), Berman et al.
patent: 4891315 (1990-01-01), Watson et al.
patent: 5314808 (1994-05-01), Tiollais et al.
Lee et al., Journal of Virology, 43, 41 (1982).
Watson et al., Nucleic Acids Research 11 , 1507 (1983).
Article published by the Institute of Infectious and Parasitic Diseases in Sophia Bulgaria entitled "The Effect of Killed Anthierpes Vaccines".
Gething et al. (1982) Nature 300, 598-603.
Sveda et al. (1982) Cell 30, 649-656.
Holland et al. (31 Jul. 1983), Eighth International Herpes Virus Workshop, Oxford, Abstracts, p. 114.
Zoler et al, (Apr. 1983), Bio/Technology; "Scientists Engineer Proteins For Cellular Export".
Spear, P.G., Herpes Viruses 1980, pp. 709-750; "Cell Membranes and Viral Envelopes", vol. 2.
Balachandran, N., et al., Infect. Immun., (1982), 37, 1132-1137; Protection Against Lethal Challenge of BALB/c Mice by Passive Transfer of Monoclonal Antibodies to Five Glycoproteins of Herpes Simplex Virus Type 2.
Dix, R.D., et al Infect. Immun., (1982), 34, 192-199; "Use of Monoclonal Antibody Directed Against Herpes Simplex Virus Glycoproteins to Protect Mice Against Acute Virus-induced Neurological Disease".
Gething et al, Modern Approaches to Vaccines--"Molecular and Chemical Basis of Virus Virulence and Immunology", pub. Cold Spring Harbor Laboratories, Proceedings of Meeting at Cold Spring Harbor, 262-268.
Alt et al Cell, (1980), 20, 293-301; "Synthesis of Secreted and Membrane-Bound Immunoglobin Mu Heavy Chains is Directed by mRNAs that Differ at Their 3' Ends".
Early et al Cell, (1980), 20, 3130319; "Two mRNAs Can Be Produced from a Single Immunoglobulin u Gene by Alternative RNA Processing Pathways".
Cheng et al, Nature, (1982), 296, 410-415; "Structure of gene for membrane and secreted murine IgD heavy chains".
Rogers et al, Cell, (1981), 26, 19-27; "Gene Segments Encoding Transmembrane Carboxyl Termini of Immunoglobulin Chains".
Mertz et al, Journal of Infectious Diseases, (1989), 161, 653-660; "Double-Blind, Placebo-Controlled Trial of a Herpes Simplex Virus Type 2 Glycoprotein Vaccine in Persons at High Risk for Genital Herpes Infection".
Chan et al, Immunology, (Jun. 1983), 49, 343-352; "Protective Immunization of mice with specific HSV-1 glycoproteins".
Schrier et al, J. Immunol., (Mar. 1983 130(3), 1413-1418; "Type-Specific Delayed Hypersensitivity and Protective Immunitu Induced by Isolated Herpes Simplex Virus Glycoprotein".
Molecular Biology of the Cell, Alberts et al, Pub. Garland Publishing Inc., New York, First Edition 1983; "The Plasma Membrane"; pp. 264-271.
Watson, et al, Science 218:381-384, 1982.
Rose, et al, Cell 30: 753-762 1982.
Middleton, et al, J. Virol. 43(3):1091-1101, 1982.
Kaufman, et al, Mol. Cell Biol. 2(11):1304-1319, 1982.
Lee, et al, 1982, PNAS 79:6612-6616.
Rose, et al., Cell 30:753-762, 1982.
Watson, et al., Science 218:381-384, 1982.
Middleton, et al, J. Virol. 43(3): 1091-1101, 1982.
Kaufman, et al., Mol. Cell. Biol. 2(11):1304-1319, 1982.
Lee, et al., PNAS 79:6612-6616, 1982.
R. G. Hope et al, Sulphated glycoproteins induced by Herpes Simplex virus. J. G. Virol. 58:399-415 (1982).
Cohen et al. (31 Jul. 1983), Eighth International Herpes Virus Workshop, Oxford, Abstracts, p. 268.
Cohen et al. (1981), International Workshop on Herpes viruses, Bologna, Abstracts, p. 89.
Wiley et al. (1981), Nature 289, 373-378.
Willis et al. (1983), J. Cellular Biol. 23, 81-94.
Frink et al. (1983), J. Virol. 45, 634-647.
Eisenberg et al. (1985), J. Virol. 56, 1014.
Gething et al. (1981), Nature 293, 620-625.
Lusky et al. (1981), Nature 293, 79-81.
Lasky et al. (Jun. 1984), Bio/Technology.
Berman et al. (1985), Science 227, 1490-1492.
Cohen et al. (1984), J. Virol. 49, 102-108.
Dietzchold et al. Synthesis of an Antigenic Determinant of the HSV gD That Stimulates the Induction of Virus-neutralizing Antibodies and Confers Protection against a Lethal Challenge of HSV, 145-149.
Eisenberg et al. (1980) J. Virol. 35, 428-435.
Webster's Ninth New Collegiate Dictionary, (1983) 1301.
Second College Edition, The American Heritage Dictionary, (1991), 384.
Bay Area Bioscience Centre, (1991), "Northern California's Bioscience Legacy", 1-33.
Middleton et al, Journal of Virology 43(3) pp. 1091-1101.
Lee et al, Proc. Natl. Acad. Sci. 79 pp. 6612-6616 (1982).
Hitzeman et al., "Expression of Hepatitis B Virus Surface Antigen in Yeast," NAR 11 , (9), 2745 (1983).
Wilson et al., "Structure of the Haemagglutinin Membrane Glycoprotein of Influenza Virus at 3.ANG. Resolution," Nature 289 , 366 (1981).
Kleid et al., "Cloned Viral Protection Vaccine for Foot-and-Mouth Disease: Responses in Cattle and Swine," Science 214 , 1125 (1981).
Rose et al., "Conditional Expression of the Vesicular Stomatisis Virus Glycoprotein Gene in Escherichia coli," PNAS USA 78 (11) (1981).
Brand et al., "Crystalline Antigen From the Influenza Virus Envelope," Nature New Biology 238, 145.
W. Weiss et al.; Nature, vol. 302, No. 3, Mar. 1983, pp. 73-74.
Bittle et al.; Nature, vol. 298, No. 1, Jul. 1982, "Protection against foot-and-mouth disease by immunization with chemically sybthesized peptide predicted from the viral nucleotide sequence"; pp. 30-33.
J. Gerin, et al.; Proc.Natl.Acad.Sci.USA; vol. 80, Apr. 1983; "Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees"; pp. 2365-2369.
G. Muller, et al.; Proc.natl.Acad.Sci.USA; vol. 79, Jan. 1982; "Anti-influenza response achieved by immunization with a synthetic conjugate"; pp. 569-573.
J.H. Weis, et al.; Nature, vol. 302, No. 3, Mar. 1983; "An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D"; pp. 72-74.
R.H. Frink, et al.; Journal of Virology, Feb. 1983, vol., 45, No. 2, pp. 634-647; "Detailed Analysis of the Portion of the Herpes Simplex Virus Type 1 Gnome Encoding Glycoprotein C".
C.C. Simonsen, et al.; Proc.Natl.Acad.Sci.USA; vol. 80, May 1983, pp. 2495-2499; "Isolation and expression of an altered mouse dihydrofolate reductase cDNA".
G. Urlaub, et al.; Proc. NatlAcad.Sci.USA; vol. 77m No. 7, Jul. 1980; pp. 4216-4220; "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity".
R.S. Goodenow, et al.; Science, vol. 215, No. 5, Feb. 1982; pp. 677-679; "Identification of a BALB/c H-2L.sup.d Gene by DNA-Mediated Gene Transfer".
Eisenberg, et al, 1980, "Comparative Structural Analysis of . . . " J. Virol. 35(2):428-435.
Watson, et al, 1982, "Herpes Simplex Virus Type-1 . . . " Science 218:381-384.
Kaufman, et al, 1982, "Construction of a modular dihydrofolate . . . " Mol. Cell. Biol. 2(11):1304-1312.
Rose, et al, "Expression from cloned cDNA . . . " Cell 30:753-762.
Chan, et al, 1983, "Protective immunization of mice . . . " Immunol. 49:343-352.
Dreesman, et al, 1982, "Antibody to hepatitis B surface . . . " Nature 295:158-160.
Berman Phillip W.
Lasky Laurence A.
Dreger Walter H.
Genentech Inc.
Smith Lynette F.
LandOfFree
Vaccine based on membrane bound proteins and process for making does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine based on membrane bound proteins and process for making , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine based on membrane bound proteins and process for making will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2043350